SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group
Carregando...
Citações na Scopus
50
Tipo de produção
article
Data de publicação
2011
Título da Revista
ISSN da Revista
Título do Volume
Editora
BIOMED CENTRAL LTD
Autores
NASCIMENTO, Raimundo M.
MACHADO-COELHO, George L. L.
MILL, Jose G.
Citação
BMC MEDICAL GENETICS, v.12, article ID 136, 6p, 2011
Resumo
Backgroundc Recent studies reported the association between SLCO1B1 polymorphisms and the development of statin-induced myopathy. In the scenario of the Brazilian population, being one of the most heterogeneous in the world, the main aim here was to evaluate SLCO1B1 polymorphisms according to ethnic groups as an initial step for future pharmacogenetic studies. Methods: One hundred and eighty-two Amerindians plus 1,032 subjects from the general urban population were included. Genotypes for the SLCO1B1 rs4149056 (c.T521C, p.V174A, exon 5) and SLCO1B1 rs4363657 (g.T89595C, intron 11) polymorphisms were detected by polymerase chain reaction followed by high resolution melting analysis with the Rotor Gene 6000 (R) instrument. Results: The frequencies of the SLCO1B1 rs4149056 and rs4363657 C variant allele were higher in Amerindians (28.3% and 26.1%) and were lower in African descent subjects (5.7% and 10.8%) compared with Mulatto (14.9% and 18.2%) and Caucasian descent (14.8% and 15.4%) ethnic groups (p < 0.001 and p < 0.001, respectively). Linkage disequilibrium analysis show that these variant alleles are in different linkage disequilibrium patterns depending on the ethnic origin. Conclusion: Our findings indicate interethnic differences for the SLCO1B1 rs4149056 C risk allele frequency among Brazilians. These data will be useful in the development of effective programs for stratifying individuals regarding adherence, efficacy and choice of statin-type.
Palavras-chave
SLCO1B1, rs4149056, statins, myopathy, Amerindian, pharmacogenetic
Referências
- AKLILLU E, 2011, EUR J CLIN PHARM
- ALVIM RO, LIPIDS HLTH DIS, V9, P128
- Link E, 2008, NEW ENGL J MED, V359, P789
- Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1
- Pasanen MK, 2006, PHARMACOGENET GENOM, V16, P873, DOI 10.1097/01.fpc.0000230416.82349.90
- Nichols GA, 2007, CLIN THER, V29, P1761, DOI 10.1016/j.clinthera.2007.08.022
- MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
- Pasanen MK, 2007, CLIN PHARMACOL THER, V82, P726, DOI 10.1038/sj.clpt.6100220
- Armitage J, 2007, LANCET, V370, P1781, DOI 10.1016/S040-6736(07)60716-8
- Ho RH, 2007, PHARMACOGENET GENOM, V17, P647, DOI 10.1097/FPC.0b013e3280ef698f
- Tirona RG, 2001, J BIOL CHEM, V276, P35669, DOI 10.1074/jbc.M103792200
- Makdisse M, 2008, ARQ BRAS CARDIOL, V91, P370
- Voora D, 2009, J AM COLL CARDIOL, V54, P1609, DOI 10.1016/j.jacc.2009.04.053
- Mwinyi J, 2008, EUR J CLIN PHARMACOL, V64, P257, DOI 10.1007/s00228-007-0409-y
- Brunham LR, 2011, PHARMACOGENOMICS J
- GHATAK A, ATHEROSCLEROSIS, V210, P337
- Gotto AM, 2006, AM J CARDIOL, V97, p3C, DOI 10.1016/j.amjcard.2005.12.005
- HAIMAN CA, CURR OPIN GENET DEV, V20, P330
- Law M, 2006, AM J CARDIOL, V97, P52
- NIEMI M, PHARM REV, V63, P157
- PUCCETTI L, ATHEROSCLEROSIS, V211, P28
- SANTOS PC, BLOOD CELLS MOL DIS, V45, P302
- SANTOS PC, 2011, CLIN CHEM LAB MED
- SANTOS PC, BMC MED GENET, V12, P13
- SANTOS PCD, AM J HYPERTENS, V24, P278
- Thompson PD, 2006, AM J CARDIOL, V97, p69C